Directions For Use
DO NOT ADMINISTER PAYLEAN™ TO SPECIES OTHER THAN PIGS.
Note to feed formulators:
Unintended inclusion of medication into animal feeds may result in residues that adversely impact trade access or the rules of professional competition. Use cleaning or flushing, or avoid sequencing feed for other species (in particular ruminant and horse feeds) immediately after manufacture of pig finisher feeds containing Paylean™.
A copy of directions for use relevant to final feed are required to be provided to the producers with each consignment of Paylean™ treated feeds. Contact Elanco Animal Health for further information.
NOT FOR USE IN BREEDING PIGS.
FOR USE IN FINISHER PIG FEEDS ONLY.
Dosage and Administration
Recommended dosages of ractopamine hydrochloride:
- 5-10ppm in final feed for increased rate of weight gain and improved feed efficiency
- 10-20ppm in final feed for increased carcass leanness and increased carcass dressing percent
PAYLEAN™ 20 PREMIX MUST BE THOROUGHLY MIXED INTO FEEDS BEFORE USE.
All calculations are based on 90% dry matter.
|Ractopamine Concentration in Final Feed g/tonne (ppm)
||Grams of Paylean™ 20 Premix to Add per Tonne of Final Feed
||1,000 (1 kg)
IMPORTANT - To ensure adequate mixing, it is recommended that a pre-blend of Paylean™ 20 Premix be made before incorporation into the total amount of complete feed. Thoroughly mix the pre-blend into a nutritionally balanced pig ration to result in a final ration containing 5 to 20ppm of ractopamine. Amino acid content of the ration may influence response to treatment. Dietary specifications should be determined in consultation with a recognised pig nutritionist in order to optimise Paylean™ benefits.
Feed complete ration containing ractopamine continuously as the sole ration to finisher pigs for the last 28-42 days prior to slaughter.
Pigs fed Paylean™ are at an increased risk for exhibiting the downer pig syndrome (could also be referred to as leg weakness syndrome). Pig handling methods to reduce the incidence of downer pigs should be thoroughly evaluated prior to initiating use of Paylean™.
WARNING: Not for use in humans. Individuals with cardiovascular disease should exercise special caution to avoid exposure. The active ingredient in Paylean™, ractopamine hydrochloride, is a beta-adrenergic agonist.